Friederike Körber1, Jürgen Frank Schäfer2. 1. Institut für Diagnostische und Interventionelle Radiologie, Schwerpunkt Kinder- und Jugendradiologie, Uniklinik Köln, Kerpener Str. 62, 50937, Köln, Deutschland. friederike.koerber@uk-koeln.de. 2. Bereich pädiatrische Radiologie, Abteilung für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Deutschland.
Abstract
BACKGROUND: Neuroblastomas are tumors of the sympathetic nervous system that arise from the sympathetic trunk and adrenal glands. Tissue compositions, molecular genetics, and overall prognosis are heterogeneous. With an incidence of 1:6000, neuroblastomas account for 5.5% of childhood tumors. They usually occur in children up to preschool age with the mean age of 14 months. Adults are very rarely affected. Imaging, especially magnetic resonance imaging (MRI), plays an essential role in diagnosis, risk stratification, and therapy control. MATERIALS AND METHODS: Based on a selective literature search in the PubMed database, the national and international societies' guidelines and study protocols, the imaging standards and the latest developments are presented. CONCLUSION: Imaging plays a key role in neuroblastomas due to the heterogeneous prognosis and the resulting very different therapy. A high degree of standardization in implementation and interpretation is important in every phase of the disease process. Sonography, MRI with diffusion weighting, and 123I‑mIBG-SPECT are essential modalities. The extent of the diffusion restriction for assessing the degree of maturity and assessing the therapeutic response is becoming increasingly important in clinical routine. Up to now, PET imaging has mostly been complementary. Newly developed PET tracers promise comprehensive diagnostics and may also play a major role in theranostics.
BACKGROUND: Neuroblastomas are tumors of the sympathetic nervous system that arise from the sympathetic trunk and adrenal glands. Tissue compositions, molecular genetics, and overall prognosis are heterogeneous. With an incidence of 1:6000, neuroblastomas account for 5.5% of childhood tumors. They usually occur in children up to preschool age with the mean age of 14 months. Adults are very rarely affected. Imaging, especially magnetic resonance imaging (MRI), plays an essential role in diagnosis, risk stratification, and therapy control. MATERIALS AND METHODS: Based on a selective literature search in the PubMed database, the national and international societies' guidelines and study protocols, the imaging standards and the latest developments are presented. CONCLUSION: Imaging plays a key role in neuroblastomas due to the heterogeneous prognosis and the resulting very different therapy. A high degree of standardization in implementation and interpretation is important in every phase of the disease process. Sonography, MRI with diffusion weighting, and 123I‑mIBG-SPECT are essential modalities. The extent of the diffusion restriction for assessing the degree of maturity and assessing the therapeutic response is becoming increasingly important in clinical routine. Up to now, PET imaging has mostly been complementary. Newly developed PET tracers promise comprehensive diagnostics and may also play a major role in theranostics.
Authors: André Oberthuer; Dilafruz Juraeva; Barbara Hero; Ruth Volland; Carolina Sterz; Rene Schmidt; Andreas Faldum; Yvonne Kahlert; Anne Engesser; Shahab Asgharzadeh; Robert Seeger; Miki Ohira; Akira Nakagawara; Paola Scaruffi; Gian Paolo Tonini; Isabelle Janoueix-Lerosey; Olivier Delattre; Gudrun Schleiermacher; Jo Vandesompele; Frank Speleman; Rosa Noguera; Marta Piqueras; Jean Bénard; Alexander Valent; Smadar Avigad; Isaac Yaniv; Richard G Grundy; Monika Ortmann; Chunxuan Shao; Manfred Schwab; Roland Eils; Thorsten Simon; Jessica Theissen; Frank Berthold; Frank Westermann; Benedikt Brors; Matthias Fischer Journal: Clin Cancer Res Date: 2014-09-17 Impact factor: 12.531
Authors: Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544
Authors: Corinna Storz; Roland Bares; Martin Ebinger; Rupert Handgretinger; Ilias Tsiflikas; Jürgen F Schäfer Journal: BMC Med Imaging Date: 2019-08-20 Impact factor: 1.930
Authors: Sebastian Gassenmaier; Ilias Tsiflikas; Jörg Fuchs; Robert Grimm; Cristian Urla; Michael Esser; Simon Maennlin; Martin Ebinger; Steven W Warmann; Jürgen F Schäfer Journal: Cancer Imaging Date: 2020-12-17 Impact factor: 3.909